多巴酚丁胺联合硝普钠治疗冠心病合并慢性心衰的安全性及有效性

The Safety and Efficacy of Dobutamine Combined with Sodium Nitroprusside in the Treatment of Coronary Heart Disease Complicated with Chronic Heart Failure

摘要: 目的：分析多巴酚丁胺联合硝普钠在治疗冠心病合并慢性心衰中的安全性及有效性。方法：回顾性选取2022年1月至2025年1月在新疆和田地区维吾尔医医院诊断为“冠心病合并慢性心衰”并且接受住院治疗的120例患者作为研究对象，根据治疗方式不同将研究对象分为试验组(60例)和对照组(60例)。试验组采用巴酚丁胺联合硝普钠治疗，对照组采用单一的多巴酚丁胺治疗。比较两组的临床疗效、四项心功能、用药后不良反应发生情况。结果：两组患者通过治疗，12周后试验组治疗总有效率显著高于对照组(P < 0.05)；治疗前两组左心室舒张末内径(LVEDD)、左心室射血分数(LVEF)、左心室收缩末内径(LVESD)、B 型钠尿肽(BNP)指标之间差异性无统计学意义(P > 0.05)；治疗后两组 LVEDD、LVESD、BNP指标比较试验组较对照组明显降低(P < 0.01)；LVEF较对照组明显增高(P < 0.01)；两组在治疗期间出现的头痛、恶心、头晕等不良反应发生率之间差异性无统计学意义(P > 0.05)。结论：多巴酚丁胺联合硝普钠在治疗冠心病合并慢性心衰中具有更高的安全性和有效性，在改善患者心功能方面优于单独使用多巴酚丁胺，因此，可作为临床治疗的优选方案。

Abstract: Objective: To analyze the safety and efficacy of dobutamine combined with sodium nitroprusside in the treatment of coronary heart disease complicated with chronic heart failure. Methods: A retrospective study was conducted on 120 patients diagnosed with “coronary heart disease complicated with chronic heart failure” and admitted for treatment at the Uyghur Medical Hospital of Hotan Region, Xinjiang, from January 2022 to January 2025. The patients were divided into an experimental group (60 cases) and a control group (60 cases) based on different treatment methods. The experimental group received dobutamine combined with sodium nitroprusside, while the control group received dobutamine alone. The clinical efficacy, four cardiac function parameters, and adverse reactions after medication were compared between the two groups. Results: After 12 weeks of treatment, the total effective rate of treatment in the experimental group was significantly higher than that in the control group (P < 0.05). Before treatment, there were no statistically significant differences between the two groups in terms of left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and B-type natriuretic peptide (BNP) (P > 0.05). After treatment, the LVEDD, LVESD, and BNP levels in the experimental group were significantly lower than those in the control group (P < 0.01), while the LVEF was significantly higher (P < 0.01). During the treatment period, there were no statistically significant differences between the two groups in the incidence of adverse reactions such as headache, nausea, and dizziness (P > 0.05). Conclusion: The combination of dobutamine and sodium nitroprusside is more effective and safer in treating coronary heart disease complicated with chronic heart failure, and it is superior to the use of dobutamine alone in improving cardiac function. Therefore, it can be considered as a preferred treatment option in clinical practice.